PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26652258-5	2015	The level of IFN was increased in GMF groups, as well as the level of IL-2 and TNF was decreased in GMF groups.	Gemifloxacin	100-103	interleukin 2	Rattus norvegicus	70-74
35203750-4	2022	The effects on the serum insulin and blood glucose levels in the Moxifloxacin and Gemifloxacin treated groups were, respectively, determined on the fifth day in both the in-vivo rabbits model and in the test subjects of the phase I clinical trial.	Gemifloxacin	82-94	insulin	Oryctolagus cuniculus	25-32
35203750-6	2022	The findings of our study suggest that Moxifloxacin and Gemifloxacin significantly (p < 0.05) reduced the blood glucose levels via a subsequent significant shift in the serum insulin levels both in the in vivo animal model and in the test subjects of the phase I clinical trial.	Gemifloxacin	56-68	insulin	Oryctolagus cuniculus	175-182
26992028-9	2016	On the other hand, pilot experiments showed that CD34+ cells exposed in vivo to GMFs (i.e., samples from MRI workers) behaved in culture similarly to sham-exposed CD34+ cells, suggesting that other cells and/or microenvironment factors might prevent GMF effects on hematopoietic stem cells in vivo.	Gemifloxacin	80-83	CD34 molecule	Homo sapiens	49-53
30530200-5	2019	Under both LD and CD conditions, reduction of GMF to NNMF prompted a significant increase of the gene expression of LHY and PRR7, whereas an opposite trend was found for GI gene expression.	Gemifloxacin	46-49	pseudo-response regulator 7	Arabidopsis thaliana	124-128
29864723-8	2018	GMF impacts on phytochrome-regulated gene expression could be attributed to alterations in phytochrome protein abundance that were also dependent on the presence of cry1, cry2 and phot1.	Gemifloxacin	0-3	cryptochrome 1	Arabidopsis thaliana	165-169
29864723-8	2018	GMF impacts on phytochrome-regulated gene expression could be attributed to alterations in phytochrome protein abundance that were also dependent on the presence of cry1, cry2 and phot1.	Gemifloxacin	0-3	cryptochrome 2	Arabidopsis thaliana	171-175
26652258-5	2015	The level of IFN was increased in GMF groups, as well as the level of IL-2 and TNF was decreased in GMF groups.	Gemifloxacin	100-103	tumor necrosis factor	Rattus norvegicus	79-82
26648740-5	2015	RESULTS: Cell proliferation and activity of the Akt pathway were significantly decreased by the GMF, while cell apoptosis, activity of p38 MAPK, and PARD3-positive cell number were significantly increased in the GMF group compared to the NC group.	Gemifloxacin	96-99	AKT serine/threonine kinase 1	Homo sapiens	48-51
26648740-5	2015	RESULTS: Cell proliferation and activity of the Akt pathway were significantly decreased by the GMF, while cell apoptosis, activity of p38 MAPK, and PARD3-positive cell number were significantly increased in the GMF group compared to the NC group.	Gemifloxacin	212-215	AKT serine/threonine kinase 1	Homo sapiens	48-51
26648740-5	2015	RESULTS: Cell proliferation and activity of the Akt pathway were significantly decreased by the GMF, while cell apoptosis, activity of p38 MAPK, and PARD3-positive cell number were significantly increased in the GMF group compared to the NC group.	Gemifloxacin	212-215	mitogen-activated protein kinase 14	Homo sapiens	135-138
26648740-5	2015	RESULTS: Cell proliferation and activity of the Akt pathway were significantly decreased by the GMF, while cell apoptosis, activity of p38 MAPK, and PARD3-positive cell number were significantly increased in the GMF group compared to the NC group.	Gemifloxacin	212-215	par-3 family cell polarity regulator	Homo sapiens	149-154
24005829-7	2014	GMF suppressed the activation of NF-kappaB, as well as the cell migration and invasion induced by tumor necrosis factor alpha (TNF-alpha).	Gemifloxacin	0-3	nuclear factor kappa B subunit 1	Homo sapiens	33-42
24005829-7	2014	GMF suppressed the activation of NF-kappaB, as well as the cell migration and invasion induced by tumor necrosis factor alpha (TNF-alpha).	Gemifloxacin	0-3	tumor necrosis factor	Homo sapiens	98-125
24005829-7	2014	GMF suppressed the activation of NF-kappaB, as well as the cell migration and invasion induced by tumor necrosis factor alpha (TNF-alpha).	Gemifloxacin	0-3	tumor necrosis factor	Homo sapiens	127-136
24005829-8	2014	GMF was shown to inhibit the phosphorylation of the inhibitor of kappaB (IkappaB) and the translocation of NF-kappaB/Snail in both cancer cell lines.	Gemifloxacin	0-3	nuclear factor kappa B subunit 1	Homo sapiens	107-116
24005829-8	2014	GMF was shown to inhibit the phosphorylation of the inhibitor of kappaB (IkappaB) and the translocation of NF-kappaB/Snail in both cancer cell lines.	Gemifloxacin	0-3	snail family transcriptional repressor 1	Homo sapiens	117-122
24005829-9	2014	This study showed that the Raf kinase inhibitor protein (RKIP), an inhibitor of IkappaB kinase, is upregulated after GMF treatment.	Gemifloxacin	117-120	phosphatidylethanolamine binding protein 1	Homo sapiens	27-55
24005829-9	2014	This study showed that the Raf kinase inhibitor protein (RKIP), an inhibitor of IkappaB kinase, is upregulated after GMF treatment.	Gemifloxacin	117-120	phosphatidylethanolamine binding protein 1	Homo sapiens	57-61
24005829-10	2014	Inhibition of RKIP by small hairpin RNA transfection significantly decreased the inhibitory effect of GMF on the NF-kappaB/Snail pathway and also inhibited cell migration and invasion.	Gemifloxacin	102-105	phosphatidylethanolamine binding protein 1	Homo sapiens	14-18
24005829-10	2014	Inhibition of RKIP by small hairpin RNA transfection significantly decreased the inhibitory effect of GMF on the NF-kappaB/Snail pathway and also inhibited cell migration and invasion.	Gemifloxacin	102-105	nuclear factor kappa B subunit 1	Homo sapiens	113-122
24005829-10	2014	Inhibition of RKIP by small hairpin RNA transfection significantly decreased the inhibitory effect of GMF on the NF-kappaB/Snail pathway and also inhibited cell migration and invasion.	Gemifloxacin	102-105	snail family transcriptional repressor 1	Homo sapiens	123-128
24005829-11	2014	Overexpression of Snail suppressed GMF-mediated metastasis inhibition and E-cadherin upregulation.	Gemifloxacin	35-38	snail family transcriptional repressor 1	Homo sapiens	18-23
24005829-15	2014	GMF induces MET by reducing NF-kappaB and Snail activation and by increasing RKIP levels.	Gemifloxacin	0-3	nuclear factor kappa B subunit 1	Homo sapiens	28-37
24005829-15	2014	GMF induces MET by reducing NF-kappaB and Snail activation and by increasing RKIP levels.	Gemifloxacin	0-3	snail family transcriptional repressor 1	Homo sapiens	42-47
24005829-15	2014	GMF induces MET by reducing NF-kappaB and Snail activation and by increasing RKIP levels.	Gemifloxacin	0-3	phosphatidylethanolamine binding protein 1	Homo sapiens	77-81
23130335-4	2012	We report here in the case of a 60-year-old male who was taking on ACE inhibitor, alpha and beta blockers and experienced a severe, resistant and biphasic anaphlylactic reaction to gemifloxacin mesylate.	Gemifloxacin	181-202	angiotensin I converting enzyme	Homo sapiens	67-70
24358058-5	2013	One of the interesting reported anti- DPP IV hits is Gemifloxacin which is used as a lead compound for the development of new DPP IV inhibitors.	Gemifloxacin	53-65	dipeptidyl peptidase 4	Homo sapiens	38-44
24358058-5	2013	One of the interesting reported anti- DPP IV hits is Gemifloxacin which is used as a lead compound for the development of new DPP IV inhibitors.	Gemifloxacin	53-65	dipeptidyl peptidase 4	Homo sapiens	126-132
24386633-5	2013	In addition, GMF suppresses the activation of NF- kappa B and cell migration and invasion induced by TNF- alpha and inhibits the TAK1/TAB2 interaction, resulting in decreased I kappa B phosphorylation and NF- kappa B nuclear translocation in SW620 cells.	Gemifloxacin	13-16	nuclear factor kappa B subunit 1	Homo sapiens	46-57
24386633-5	2013	In addition, GMF suppresses the activation of NF- kappa B and cell migration and invasion induced by TNF- alpha and inhibits the TAK1/TAB2 interaction, resulting in decreased I kappa B phosphorylation and NF- kappa B nuclear translocation in SW620 cells.	Gemifloxacin	13-16	tumor necrosis factor	Homo sapiens	101-111
24386633-5	2013	In addition, GMF suppresses the activation of NF- kappa B and cell migration and invasion induced by TNF- alpha and inhibits the TAK1/TAB2 interaction, resulting in decreased I kappa B phosphorylation and NF- kappa B nuclear translocation in SW620 cells.	Gemifloxacin	13-16	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	129-133
24386633-5	2013	In addition, GMF suppresses the activation of NF- kappa B and cell migration and invasion induced by TNF- alpha and inhibits the TAK1/TAB2 interaction, resulting in decreased I kappa B phosphorylation and NF- kappa B nuclear translocation in SW620 cells.	Gemifloxacin	13-16	nuclear factor kappa B subunit 1	Homo sapiens	205-216
24386633-6	2013	Furthermore, Snail, a critical transcriptional factor of EMT, was downregulated after GMF treatment.	Gemifloxacin	86-89	snail family transcriptional repressor 1	Homo sapiens	13-18
24386633-7	2013	Overexpression of Snail by cDNA transfection significantly decreases the inhibitory effect of GMF on EMT and cell migration and invasion.	Gemifloxacin	94-97	snail family transcriptional repressor 1	Homo sapiens	18-23
21864659-0	2011	Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin.	Gemifloxacin	66-78	phosphoglycolate phosphatase	Homo sapiens	23-27
21864659-0	2011	Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin.	Gemifloxacin	66-78	ATP binding cassette subfamily C member 2	Homo sapiens	32-36
21864659-11	2011	This significant reduction in efflux ratio further confirmed the substrate specificity of gemifloxacin towards P-gp and MRP2.	Gemifloxacin	90-102	phosphoglycolate phosphatase	Homo sapiens	111-115
21864659-11	2011	This significant reduction in efflux ratio further confirmed the substrate specificity of gemifloxacin towards P-gp and MRP2.	Gemifloxacin	90-102	ATP binding cassette subfamily C member 2	Homo sapiens	120-124
21864659-2	2011	The primary objective of this study was to assess short and long term affinities of gemifloxacin towards efflux transporters (P-gp, MRP2) and nuclear hormone receptor (PXR).	Gemifloxacin	84-96	phosphoglycolate phosphatase	Homo sapiens	126-130
21864659-14	2011	In conclusion, our studies demonstrated that gemifloxacin is effluxed by both P-gp and MRP2.	Gemifloxacin	45-57	phosphoglycolate phosphatase	Homo sapiens	78-82
21864659-2	2011	The primary objective of this study was to assess short and long term affinities of gemifloxacin towards efflux transporters (P-gp, MRP2) and nuclear hormone receptor (PXR).	Gemifloxacin	84-96	ATP binding cassette subfamily C member 2	Homo sapiens	132-136
21864659-14	2011	In conclusion, our studies demonstrated that gemifloxacin is effluxed by both P-gp and MRP2.	Gemifloxacin	45-57	ATP binding cassette subfamily C member 2	Homo sapiens	87-91
21864659-2	2011	The primary objective of this study was to assess short and long term affinities of gemifloxacin towards efflux transporters (P-gp, MRP2) and nuclear hormone receptor (PXR).	Gemifloxacin	84-96	nuclear receptor subfamily 1 group I member 2	Homo sapiens	168-171
21864659-4	2011	Cellular accumulation of calcein-AM was further determined to confirm the affinity of gemifloxacin towards P-gp and MRP2.	Gemifloxacin	86-98	phosphoglycolate phosphatase	Homo sapiens	107-111
21864659-4	2011	Cellular accumulation of calcein-AM was further determined to confirm the affinity of gemifloxacin towards P-gp and MRP2.	Gemifloxacin	86-98	ATP binding cassette subfamily C member 2	Homo sapiens	116-120
20579213-2	2010	Most cases of GMF are CD4 positive, and CD8 positive cases are extremely rare.	Gemifloxacin	14-17	CD4 molecule	Homo sapiens	22-25
21764262-3	2011	Using murine J774 macrophages and human THP-1 monocytes, we show that gemifloxacin accumulates more than ciprofloxacin and even moxifloxacin.	Gemifloxacin	70-82	GLI family zinc finger 2	Homo sapiens	40-45
21764262-5	2011	Gemifloxacin was also a weaker substrate than ciprofloxacin for the efflux transporter Mrp4 active in J774 macrophages.	Gemifloxacin	0-12	prolactin family 2, subfamily c, member 5	Mus musculus	87-91
20579213-3	2010	Herein, we report a case of CD8-positive GMF.	Gemifloxacin	41-44	CD8a molecule	Homo sapiens	28-31
20579213-10	2010	These findings were consistent with CD8-positive GMF.	Gemifloxacin	49-52	CD8a molecule	Homo sapiens	36-39
20579213-13	2010	In addition, the prognosis of GMF, especially CD8-positive GMF, is still controversial.	Gemifloxacin	59-62	CD8a molecule	Homo sapiens	46-49
15664487-0	2005	In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.	Gemifloxacin	20-32	cullin 9	Mus musculus	98-102
18989859-8	2008	One of our interesting potent anti-DPP IV hits is the fluoroquinolone gemifloxacin (IC(50)=1.12 muM).	Gemifloxacin	70-82	dipeptidyl peptidase 4	Homo sapiens	35-41
18989859-9	2008	The fact that gemifloxacin was recently reported to potently inhibit the prodiabetic target glycogen synthase kinase 3beta (GSK-3beta) suggests that gemifloxacin is an excellent lead for the development of novel dual antidiabetic inhibitors against DPP IV and GSK-3beta.	Gemifloxacin	14-26	glycogen synthase kinase 3 beta	Homo sapiens	92-122
18989859-9	2008	The fact that gemifloxacin was recently reported to potently inhibit the prodiabetic target glycogen synthase kinase 3beta (GSK-3beta) suggests that gemifloxacin is an excellent lead for the development of novel dual antidiabetic inhibitors against DPP IV and GSK-3beta.	Gemifloxacin	14-26	glycogen synthase kinase 3 beta	Homo sapiens	124-133
18989859-9	2008	The fact that gemifloxacin was recently reported to potently inhibit the prodiabetic target glycogen synthase kinase 3beta (GSK-3beta) suggests that gemifloxacin is an excellent lead for the development of novel dual antidiabetic inhibitors against DPP IV and GSK-3beta.	Gemifloxacin	14-26	dipeptidyl peptidase 4	Homo sapiens	249-255
18989859-9	2008	The fact that gemifloxacin was recently reported to potently inhibit the prodiabetic target glycogen synthase kinase 3beta (GSK-3beta) suggests that gemifloxacin is an excellent lead for the development of novel dual antidiabetic inhibitors against DPP IV and GSK-3beta.	Gemifloxacin	14-26	glycogen synthase kinase 3 beta	Homo sapiens	260-269
18989859-9	2008	The fact that gemifloxacin was recently reported to potently inhibit the prodiabetic target glycogen synthase kinase 3beta (GSK-3beta) suggests that gemifloxacin is an excellent lead for the development of novel dual antidiabetic inhibitors against DPP IV and GSK-3beta.	Gemifloxacin	149-161	glycogen synthase kinase 3 beta	Homo sapiens	92-122
18989859-9	2008	The fact that gemifloxacin was recently reported to potently inhibit the prodiabetic target glycogen synthase kinase 3beta (GSK-3beta) suggests that gemifloxacin is an excellent lead for the development of novel dual antidiabetic inhibitors against DPP IV and GSK-3beta.	Gemifloxacin	149-161	glycogen synthase kinase 3 beta	Homo sapiens	124-133
18989859-9	2008	The fact that gemifloxacin was recently reported to potently inhibit the prodiabetic target glycogen synthase kinase 3beta (GSK-3beta) suggests that gemifloxacin is an excellent lead for the development of novel dual antidiabetic inhibitors against DPP IV and GSK-3beta.	Gemifloxacin	149-161	dipeptidyl peptidase 4	Homo sapiens	249-255
18989859-9	2008	The fact that gemifloxacin was recently reported to potently inhibit the prodiabetic target glycogen synthase kinase 3beta (GSK-3beta) suggests that gemifloxacin is an excellent lead for the development of novel dual antidiabetic inhibitors against DPP IV and GSK-3beta.	Gemifloxacin	149-161	glycogen synthase kinase 3 beta	Homo sapiens	260-269
18324764-0	2008	Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.	Gemifloxacin	210-222	glycogen synthase kinase 3 beta	Homo sapiens	117-147
18324764-4	2008	The validity of the QSAR equation and the associated pharmacophores was established by the identification of three nanomolar GSK-3beta inhibitors retrieved from our in-house-built structural database of established drugs, namely, hydroxychloroquine, cimetidine, and gemifloxacin.	Gemifloxacin	266-278	glycogen synthase kinase 3 beta	Homo sapiens	125-134
19468056-4	2009	It is denoted as genetic modification of flux (GMF), which couples two algorithms that we have developed: modified control effective flux (mCEF) and enzyme control flux (ECF).	Gemifloxacin	47-50	AF4/FMR2 family, member 4	Mus musculus	139-143
15728901-6	2005	While control mice died within 6 days, gemifloxacin at doses of 25 and 50 mg/kg of body weight was highly effective (survival rates, 90 to 100%) against the wild-type strain and against mutants harboring a single mutation, corresponding to area under the time-versus-serum concentration curve at 24 h (AUC(24))/MIC ratios of 56.5 to 113, and provided a 40% survival rate against a mutant with a double mutation (parC and gyrA).	Gemifloxacin	39-51	cullin 9	Mus musculus	412-416
15728901-9	2005	Gemifloxacin preferentially selected for parC mutants both in vitro and in vivo.	Gemifloxacin	0-12	cullin 9	Mus musculus	41-45
15008941-4	2004	Nuclear extracts of the human monocyte cell line, THP-1, were used in the electrophoretic mobility shift assay to determine whether gemifloxacin affects nuclear factor-kappa B (NF-kappa B) activation.	Gemifloxacin	132-144	nuclear factor kappa B subunit 1	Homo sapiens	153-175
15497755-0	2004	In vitro anti-inflammatory effects and immunomodulation by gemifloxacin in stimulated human THP-1 monocytes.	Gemifloxacin	59-71	GLI family zinc finger 2	Homo sapiens	92-97
15497755-3	2004	The effects of gemifloxacin on DNA synthesis and killing of S. aureus was assessed in bacteria alone and in those bacteria phagocytosed by THP-1 monocytes over 24 h. Gemifloxacin in stimulated THP-1 monocytes over the first 30 min caused an increase in c-AMP, NO, H2O2 and TNFalpha levels and protein kinase C, NADPH oxidase, glutathione reductase, NAG and cathepsin D activities.	Gemifloxacin	166-178	GLI family zinc finger 2	Homo sapiens	139-144
15497755-3	2004	The effects of gemifloxacin on DNA synthesis and killing of S. aureus was assessed in bacteria alone and in those bacteria phagocytosed by THP-1 monocytes over 24 h. Gemifloxacin in stimulated THP-1 monocytes over the first 30 min caused an increase in c-AMP, NO, H2O2 and TNFalpha levels and protein kinase C, NADPH oxidase, glutathione reductase, NAG and cathepsin D activities.	Gemifloxacin	166-178	GLI family zinc finger 2	Homo sapiens	193-198
15497755-6	2004	These effects were at a higher magnitude at 24 h. Gemifloxacin initiates a phagocyticidal effect of THP-1 monocytes at an early time of 30 min which plays a role in killing bacteria but a higher magnitude of killing of bacteria occurs later by a standard static mechanism.	Gemifloxacin	50-62	GLI family zinc finger 2	Homo sapiens	100-105
15008941-4	2004	Nuclear extracts of the human monocyte cell line, THP-1, were used in the electrophoretic mobility shift assay to determine whether gemifloxacin affects nuclear factor-kappa B (NF-kappa B) activation.	Gemifloxacin	132-144	nuclear factor kappa B subunit 1	Homo sapiens	177-187
15008941-5	2004	In addition, RNA from THP-1 cells was used in Northern blots to determine whether inhibition of secretion of IL-1 beta and TNF-alpha by gemifloxacin occurred at the transcription or translation level.	Gemifloxacin	136-148	interleukin 1 beta	Homo sapiens	109-118
15008941-5	2004	In addition, RNA from THP-1 cells was used in Northern blots to determine whether inhibition of secretion of IL-1 beta and TNF-alpha by gemifloxacin occurred at the transcription or translation level.	Gemifloxacin	136-148	tumor necrosis factor	Homo sapiens	123-132
10997596-2	2000	Gemifloxacin demonstrated excellent correlation between efficacy and the AUC0-24h/MIC ratio whereas there was little correlation with time above MIC.	Gemifloxacin	0-12	microphthalmia Japan	Mus musculus	82-85
12151195-2	2002	The activity of gemifloxacin, a new fluoroquinolone, was measured against a collection of susceptible wild-type strains (MIC(90,) 0.008 microg/ml for both beta-lactamase-negative and -positive strains) and strains less susceptible to quinolones (MIC(90,) 1 microg/ml).	Gemifloxacin	16-28	beta-lactamase TEM-1	Haemophilus influenzae	155-169
11158752-13	2001	Gemifloxacin was generally well tolerated, although one subject was withdrawn from the study after 6 days at 640 mg for mild, transient elevations of alanine aminotransferase and aspartate aminotransferase not associated with any clinical signs or symptoms.	Gemifloxacin	0-12	glutamic--pyruvic transaminase	Homo sapiens	150-174
10997596-9	2000	The lower AUC0-24h/MIC ratio was especially noticeable for the efflux mutants suggesting that the quinolone efflux mechanism may be down-regulated in vivo and may be of minimal relevance to the clinical activity of gemifloxacin against S. pneumoniae.	Gemifloxacin	215-227	microphthalmia Japan	Mus musculus	19-22